Plenary Speaker

Richard Bonneau, PhD

VP ML for Drug Discovery, gRED Computational Sciences @ Genentech

Integrating Generative AI with Active Learning To Power Next Generation Drug Discovery

Plenary Speaker

Zhichao Liu, PhD

Director of AI and Digital Information @ Boehringer Ingelheim 

Harnessing Generative AI in Nonclinical Safety Evaluation

Tom Forest, DVM, PhD, DACVP

Distinguished Scientist @ Merck

Comparison of Supervised and Unsupervised Machine Learning Scoring of Histology Images

Magali Guffroy, DVM, Diplomate ACVP

Global Head of Pathology, Preclinical Safety @ AbbVie

Unique Platform Toxicities of ADC's - Learnings over the last decade 

Fangyao Hu, PhD

Tech Lead Manager Digital Pathology | Safety Assessment @ Genentech

Model Detection of the Seen and Unseen: A Multi-paradigm Approach to Histologic Anomaly Detection

Pia Kasperkovitz, PhD

Senior Director Toxicology @ Bright Peak Therapeutics

Case study: Regulatory Interactions and Path To IND For a Novel Antibody-protein Conjugate

Mahua Roy, PhD

Associate Director, Translational PKPD ; ADC Clinical Pharmacology Quantitative Pharmacology @ AstraZeneca

Integrating PKPD Modeling and Clinical Toxicity Meta-Analysis Towards Therapeutic Index Prediction for Antibody-Drug Conjugate

Kimberly Homan, PhD

Sr. Director of Complex in Vitro Systems Group @ Genentech

Opportunities and Insights From Pharma On the Use of NAMs to Replace Large Animal Studies in Nonclinical Safety Assessments for Biotherapeutics

Jessica D. Sims, PhD, DABT

Principal Scientist-Toxicology @ Genentech

Safety Considerations for Developing Molecular Glues and other Targeted Protein Degraders 

Lauren Black, PhD

Distinguished Scientist @ Charles River Laboratories

Supporting Clinical Trials for Non-Cancer Cell Therapies - From Patient and Treatment Plans, Backwards

Natacha Bohin, PhD

Associate Director @ AstraZeneca

Advancing Pre-clinical Safety Assessment with Advanced Cell Models

Xiaoting Wang, PhD, DABT

Director, Translational Safety and Bioanalytical Sciences @ Amgen

Global Off-target Profiling of Targeted Protein Degraders With a Cell-based Proteomics Platform

Jillian Wendel, PhD

Study Director and Neurobehavioral Subject Matter Expert @ Labcorp

Insights into Building a Robust Virtual Control Database and Selection Methods for Use on Retrospective Analysis of Nonclinical Safety Assessment Studies

Haley Neff-LaFord, PhD, DABT

Executive Director, ADC Therapeutic Area Lead @ Pfizer 

Opportunities and Challenges for Preclinical Assessment of Next Generation ADCs

Christina Zuch de Zafra, PhD

Director, Nonclinical Sciences @ Pfizer

Nonclinical Safety Strategies for ADC Development - Looking back to move forward.

David Gallegos, PhD

Senior Scientist @ Takeda

Context-Specific Applications Across Spatial Transcriptomic Platforms

Sonja Schrepfer, MD, PhD

Scientific Founder & Senior VP @ Sana Biotechnology

Protecting Allogeneic Transplants From Immune Rejection Is the Key To Bringing Cell-based Therapies to Patients

Laura Leung, PhD

Principal Scientist, Toxicology @ Avidity Biosciences, Inc.

Nonclinical Safety Assessment of Antibody-Oligo Conjugates from IND-Enabling Through Late-Stage Clinical Trials  

 Diana Lac, PhD

Toxicologist @ Genentech

The Use of In Vitro Assays for Novel Payload Selection in New-Generation ADC's

Byunghak (BK) Kang, PhD

Associate Director @ Novartis

Computational Pathology Applied to Toxicologic Pathology

Nick Brown, PhD

Group Leader, Client Services @ Charles River Laboratories, UK

Leveraging the Proteome: Harnessing In Vitro NAMs to Understand  Human and Non-human Protein Binding Profiles for Therapeutics

Raibatak Das, PhD

Founder & Scientific Director @ Quantilogix, LLC 

Modeling Approaches to Support Dose Selection for Cell and Gene Therapies

 Dinah Misner, PhD

Vice President @ Aligos Therapeutics

Oligonucleotides in Discovery: A Case Study of an siRNA for the Treatment of Chronic Hepatitis B Virus Infection

Chris Strock, PhD

VP US ADMET Operations @ Cyprotex

An AI Approach to Drug-Induced Liver Injury Risk: Prediction of Safe Maximum Doses from Toxicogenomic Profile 

Taci Pereira, PhD

Chief Executive Officer @ Systemic Bio

h-VIOS: A Human-relevant Drug Discovery and Development Platform Using Bioprinted Tissues

David A. Gallegos, PhD

Senior Scientist @ Takeda

Preclinical Neurotoxicity Prediction Using a High-Throughput Neural Spheroid Model